IF-IC, FC-FP
H
Endogenous
Rabbit IgG
#P41134
3397
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Immunofluorescence (Immunocytochemistry) | 1:1000 |
| Flow Cytometry (Fixed/Permeabilized) | 1:50 - 1:200 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant human ID1 protein.
Background
Inhibitor of DNA-binding/Differentiation (ID) proteins are a family of proteins that function to repress the activity of basic helix-loop-helix (bHLH) transcription factors. There are four known ID proteins in humans (ID1-4), all of which contain a helix-loop-helix domain but lack a basic DNA-binding domain. Heterodimerization with bHLH transcription factors, therefore, functions to sequester bHLH proteins and prevent their binding to DNA (1). ID proteins play important functional roles in development, primarily by inhibiting premature differentiation of stem/progenitor cells (1,2). ID1 plays important regulatory roles downstream of TGF-β and BMP signaling by inhibiting various transcription factors (3,4). SMAD3 is capable of binding to the ID1 promoter, causing upregulation in response to TGF-β (5). High expression of ID1 is associated with increased cancer growth and migration by inhibiting cell cycle regulators p16, p21, and p27 (6,7). ID1 as a therapeutic target is context dependent. While high expression of ID1 is generally associated with poor prognosis, drug sensitivity can vary greatly depending on tumor type (8-10).
- Yokota, Y. (2001) Oncogene 20, 8290-8.
- Hong, S.H. et al. (2011) J Cell Sci 124, 1445-52.
- Di, K. et al. (2006) Biol Cell 98, 523-33.
- Miyazono, K. and Miyazawa, K. (2002) Sci STKE 2002, pe40.
- Liang, Y.Y. et al. (2009) Cell Res 19, 140-8.
- Asirvatham, A.J. et al. (2007) Prostate 67, 1411-20.
- Alani, R.M. et al. (2001) Proc Natl Acad Sci USA 98, 7812-6.
- Castañon, E. et al. (2013) J Transl Med 11, 13.
- Li, L. et al. (2017) Oncol Lett 13, 3014-3024.
- Tan, H.Y. et al. (2020) Cancer Lett 475, 109-118.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Applications Key
IF-IC: Immunofluorescence (Immunocytochemistry) FC-FP: Flow Cytometry (Fixed/Permeabilized)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.